Dynavax Technologies Corporation - Common Stock (DVAX)
15.38
+4.25 (38.19%)
NASDAQ · Last Trade: Dec 24th, 6:42 PM EST
Detailed Quote
Previous Close
11.13
Open
15.49
Bid
15.37
Ask
15.38
Day's Range
15.38 - 15.49
52 Week Range
9.200 - 15.49
Volume
30,756,618
Market Cap
1.98B
PE Ratio (TTM)
-41.57
EPS (TTM)
-0.4
Dividend & Yield
N/A (N/A)
1 Month Average Volume
2,982,868
Chart
About Dynavax Technologies Corporation - Common Stock (DVAX)
Dynavax Technologies is a biotechnology company focused on developing innovative immunotherapies to treat and prevent infectious diseases and cancer. Its research emphasizes harnessing the body's immune system to generate strong and durable responses, particularly through the use of its proprietary toll-like receptor (TLR) technology. The company is known for its commitment to advancing novel vaccine approaches and immune-modulating therapies, with a portfolio that includes products aimed at improving patient outcomes and enhancing immune response in various therapeutic areas. Dynavax collaborates with other organizations to drive advancements in biomedical research and bring transformative solutions to healthcare. Read More
As of today, December 24, 2025, the global pharmaceutical landscape is witnessing a profound consolidation of power within specialty medicine and immunology. Sanofi (NASDAQ: SNY; Euronext: SAN), the French healthcare titan that has spent the last five years aggressively shedding its legacy skin, has punctuated its transformation with the $2.2 billion acquisition of Dynavax Technologies [...]
Introduction On December 24, 2025, the biotechnology sector received its most significant holiday gift in years. Sanofi (NASDAQ: SNY; Euronext: SAN) announced a definitive agreement to acquire Dynavax Technologies (NASDAQ: DVAX) in an all-cash transaction valued at approximately $2.2 billion. The announcement triggered a 39% surge in Dynavax shares, thrusting the Emeryville-based vaccine specialist into [...]
Let's have a look at what is happening on the US markets one hour before the close of the markets on Wednesday. Below you can find the top gainers and losers in today's session.
Looking for insights into the US markets in the middle of the day on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
In a blockbuster conclusion to the 2025 trading year, Dynavax Technologies (NASDAQ:DVAX) saw its stock price skyrocket by nearly 40% in premarket trading this morning, December 24, 2025. The surge follows the official announcement that global pharmaceutical giant Sanofi (NASDAQ:SNY) has entered into a definitive agreement to acquire
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Dynavax Technologies Corporation (NASDAQ: DVAX) to Sanofi for $15.50 per share in cash is fair to Dynavax shareholders.
Rep. Haley Stevens (D-Mich.) announced that she will introduce articles of impeachment against Health and Human Services Secretary Robert F. Kennedy Jr.
President Donald Trump on Monday offered advice on childhood vaccination schedules, encouraging parents to split up certain immunizations and delay certain others, in sharp contradiction to current medical recommendations.
Sen. Elizabeth Warren (D-Mass.) on Thursday criticized the Centers for Disease Control and Prevention's vaccine advisory panel following its controversial vote to delay the combined measles, mumps, rubella, and varicella or MMRV vaccine for children under 4 years old.
Deep Track Capital, LP, (together with its affiliates, “Deep Track” or “we”), one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ: DVAX) (“Dynavax”, “DVAX” or the “Company”), with ownership of approximately 14.82% of the Company’s outstanding shares, today issued a letter to shareholders detailing the benefits of electing Deep Track’s four nominees – Brett Erkman, Jeffrey Farrow, Michael Mullette and Donald Santel – to the Board of Directors (the “Board”) at the upcoming 2025 Annual Meeting of Shareholders (the “Annual Meeting”) on June 11, 2025.
Deep Track Capital, LP, (together with its affiliates, “Deep Track” or “we”), one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ: DVAX) (“Dynavax”, “DVAX” or the “Company”), with ownership of approximately 14.82% of the Company’s outstanding shares, today announced that leading independent proxy advisory firm Glass, Lewis & Co. (“Glass Lewis”) has recommended shareholders support boardroom change by voting for the election of Deep Track director nominees Brett Erkman and Donald Santel to the Company’s Board of Directors (the “Board”) at the 2025 Annual Meeting of Shareholders (the “Annual Meeting”).
Deep Track Capital, LP, (together with its affiliates, “Deep Track” or “we”), one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ: DVAX) (“Dynavax”, “DVAX” or the “Company”), with ownership of approximately 14.82% of the Company’s outstanding shares, today issued the following statement in response to a report issued by Institutional Shareholder Services Inc. (“ISS”) regarding the election of directors to the Company’s Board of Directors (the “Board”) at the 2025 Annual Meeting of Stockholders (the “Annual Meeting”).
Deep Track Capital, LP, (together with its affiliates, “Deep Track” or “we”), one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ: DVAX) (“Dynavax”, “DVAX” or the “Company”), with ownership of approximately 14.82% of the Company’s outstanding shares, today issued a letter to shareholders in connection with its nomination of four highly qualified candidates for election to the Company’s Board of Directors (the “Board”) at the 2025 Annual Meeting of Stockholders (the “Annual Meeting”).
